Abstract Number: 5

Efficacy of certolizumab pegol in psoriasis patients failing to respond to etanercept in an ongoing, phase 3, randomised controlled study

M. Augustin1, J. Węgłowska2, M. Lebwohl3, V. Piguet4, H. Sofen5, A. Blauvelt6, L. Peterson7, C. Arendt8, R. Rolleri7

Meeting: 2019 Dermcoll

Session Information

Date: -

Session Title: All Abstracts

Session Time: -

Introduction: The Fc-free, PEGylated, anti-tumour necrosis factor (TNF) certolizumab pegol (CZP), has shown efficacy in adults with plaque psoriasis (PSO) over 48 weeks’ (wks’) treatment.1,2
Objectives: To assess the efficacy of CZP in patients who failed to respond (